Skip to main content

Month: March 2022

Cardlytics Announces Fourth Quarter and Fiscal Year 2021 Financial Results

ATLANTA, March 01, 2022 (GLOBE NEWSWIRE) — Cardlytics, Inc., (NASDAQ: CDLX), an advertising platform in banks’ digital channels, today announced financial results for the fourth quarter and fiscal year ended December 31, 2021. Supplemental information is available on the Investor Relations section of the Cardlytics’ website at http://ir.cardlytics.com/. “We are really pleased with our Q4 results, which exceeded the high end of our guidance for billings, revenue and adjusted contribution. The strong performance comes as we continue to make progress across our strategic priorities,” said Lynne Laube, CEO & Co Founder of Cardlytics. “Our Q4 results reflect year-over-year growth across all of our advertiser verticals, and growth over 2019 in every vertical except travel. Each sales vertical contributed to Cardlytics...

Continue reading

Apollo Announces First Close of Global Wealth Acquisition of Griffin

NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced a first close in its previously announced transaction with Griffin Capital (“Griffin”). Apollo has completed the acquisition of Griffin’s wealth distribution business, now part of Apollo Global Wealth. Apollo expects to hold a final close to add Griffin’s individual-investor focused products and associated asset management team in the second quarter of 2022. With today’s close, Apollo adds approximately 60 client-facing distribution professionals working across the wealth management landscape and who are particularly well-established in the independent channel, a complement to Apollo’s focus to-date on private banks, wirehouses, institutional RIAs and family offices. It also transitions critical marketing, technology and operational infrastructure to...

Continue reading

1stDibs Reports Fourth Quarter and Full Year 2021 Financial Results

Q4 Gross Merchandise Value Increased 11% Year-Over-Year to $117 millionQ4 Net Revenue Increased 13% Year-Over-Year to $26.9 million NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) — 1stdibs.com, Inc. (NASDAQ: DIBS), a leading online marketplace for luxury design products, today reported financial results for its fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 Financial HighlightsNet revenue was $26.9 million, an increase of 13% year-over-year. Gross profit was $16.6 million, a decrease of 3% year-over-year. Gross margin was 61.7%, compared to 72.0% in the fourth quarter 2020. GAAP net loss was $8.1 million, compared to $1.6 million in the fourth quarter 2020. Non-GAAP Adjusted EBITDA and Adjusted EBITDA Margin was $(6.7) million and (25.0)%, respectively, compared to $(0.9) million and (3.7)%, respectively,...

Continue reading

Certara Reports Fourth Quarter and Full Year 2021 Financial Results

PRINCETON, N.J., March 01, 2022 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2021 and updated guidance for 2022. Fourth Quarter Highlights:Revenue was $75.3 million, compared to $64.6 million in the fourth quarter of 2020, representing growth of 17% over the fourth quarter of 2020. Excluding Pinnacle 21, revenue was $69.3 million, representing growth of 7% over the fourth quarter of 2020. Net loss was $9.7 million, compared to net loss of $54.5 million in the fourth quarter of 2020, representing a decrease of $44.7 million over the fourth quarter of 2020. Adjusted EBITDA was $28.2 million, compared to $22.2 million in the fourth quarter of 2020, representing growth of 27% over the fourth quarter of 2020.Full Year...

Continue reading

CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update

– Encouraging activity for CX-2029 in Phase 2 expansion study in squamous non-small cell lung cancer (sqNSCLC) reported in 2021 – – First-in-human study of CX-904 in advanced solid tumors to be initiated in first half of 2022 – – Initial data for Arms A and B in Phase 2 study of praluzatamab ravtansine in breast cancer expected in second half of 2022 – SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today reported fourth quarter and full year 2021 financial results, and provided a business update. “2021 was a successful year of sustained execution and delivery on CytomX’s commitment to destroying cancer differently, highlighted by the significant progress advancing...

Continue reading

GCP Applied Technologies Reports Fourth Quarter and Full Year 2021 Results

ALPHARETTA, Ga., March 01, 2022 (GLOBE NEWSWIRE) — GCP Applied Technologies Inc. (NYSE: GCP) (GCP or the Company), a leading global provider of construction products, today announced financial and operating results for the fourth quarter and full year 2021. Fourth Quarter 2021 HighlightsNet sales $244.3 million, an increase of 0.7% Selling, general and administrative expenses of $64.6 million, a decrease of 1.7% Income from continuing operations attributable to GCP shareholders of $1.8 million Adjusted EBIT* of $18.8 million Adjusted EBITDA* of $31.0 million Adjusted EPS of $0.12Full Year 2021 HighlightsNet sales of $970.1 million, an increase of 7.4% Selling, general and administrative expenses of $254.6 million, a decrease of 3.7% Income from continuing operations attributable to GCP shareholders of $21.5 million Adjusted...

Continue reading

SLR Investment Corp. Announces Quarter and Fiscal Year Ended December 31, 2021 Financial Results;

Strong Origination Volumes Drive SLRC to its Target Leverage Range; Declares Quarterly Distribution of $0.41 Per Share for Q1, 2022 NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) — SLR Investment Corp. (NASDAQ: SLRC) (the “Company” or “SLRC”) today reported net investment income of $14.9 million, or $0.35 per share, for the fourth quarter of 2021. For the fiscal year ended December 31, 2021, the Company reported net investment income of $60.9 million, or $1.44 per share. At December 31, 2021, net asset value (NAV) was $19.93 per share. The Company’s Board of Directors declared a first quarter 2022 distribution of $0.41 per share, payable on April 1, 2022 to stockholders of record on March 18, 2022. The specific tax characteristics of the distribution will be reported to stockholders on Form 1099 after the end of the calendar year. HIGHLIGHTS:...

Continue reading

Maui Land & Pineapple Company, Inc. Reports Fourth Quarter and Fiscal 2021 Results

KAPALUA RESORT, Hawaii, March 01, 2022 (GLOBE NEWSWIRE) — Maui Land & Pineapple Company, Inc. (NYSE: MLP) today announced financial results for the fourth quarter and year ended December 31, 2021. Results for Year Ended December 31, 2021 Net loss increased to $(3.4) million, or $(0.18) per share, compared to a net loss of $(2.6) million, or $(0.14) per share, for the year ended December 31, 2020. Operating revenues increased to $12.4 million, compared to $7.5 million for the year ended December 31, 2020. Total comprehensive income increased to $2.6 million, or $0.13 per share,, compared to a comprehensive loss of $(3.5) million, or $(0.19) per share, for the year ended December 31, 2020. The Company recorded a pension gain adjustment of $6.0 million, or $0.31 per share, compared to a pension loss adjustment of $(0.9) million,...

Continue reading

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2021 Results

Company Reports Record Revenues SOLANA BEACH, Calif., March 01, 2022 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its fourth quarter and full-year ended December 31, 2021. 2021 Full Year and Fourth Quarter HighlightsReported fourth quarter 2021 revenue of $4.3 million, an increase of 15% compared with the fourth quarter of 2020. Reported revenue of $16.3 million for the full year 2021, a 27% increase over 2020 and representing the seventh consecutive year of growth.Increased biologics and drug delivery revenue to $6.8 million for the full year 2021, a 31% increase over 2020.Supported 929 cases in 2021 despite the continued challenges posed by the COVID-19 pandemic.Completed...

Continue reading

Advantage Solutions Reports Solid Fourth Quarter and Full Fiscal Year 2021 Financial Results and Provides Initial 2022 Outlook

IRVINE, Calif., March 01, 2022 (GLOBE NEWSWIRE) — Advantage Solutions Inc. (NASDAQ: ADV) (“Advantage,” the “Company,” “we” or “our”), a leading provider of outsourced sales and marketing services to consumer goods manufacturers and retailers, today reported financial results for its fiscal fourth quarter and full fiscal year ended December 31, 2021. “We had a solid finish to 2021, converting strong revenue growth to healthy EBITDA gains,” said Advantage Solutions Chief Executive Officer Tanya Domier. “As we emerge from Omicron, our sampling events grew 20% quarter over quarter, while at-home demand stayed healthy, driven by robust pricing and modest unit growth. Our higher margin digital services grew double digits. We continued to invest heavily in recruiting and retention to stand up thousands of new associates, funded in part...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.